Keyphrases
Tumor Cells
100%
Monoclonal Antibody
100%
Integrin
100%
Direct Targeting
100%
Tumor Growth
40%
Lung
20%
Cell-to-cell
20%
Clinical Trials
20%
Antitumor Activity
20%
High Dose
20%
Breast Cancer
20%
Species Traits
20%
Endothelial Cells
20%
Kidney
20%
Prostate Cancer
20%
Biological Activity
20%
Ovarian Cancer
20%
Angiogenesis
20%
Serum Levels
20%
Flow Cytometric Analysis
20%
Solid Tumors
20%
Dose Effect
20%
Endothelium
20%
Cancer Cell Lines
20%
High-level Expression
20%
Tumor Metastasis
20%
Osteoclast
20%
Phase II Trial
20%
Osteolytic
20%
Antiangiogenic
20%
Antitumor
20%
Therapeutic Targeting
20%
Cancer-related
20%
Angiogenic
20%
Pathologic Processes
20%
Role in Cancer
20%
Antibody-dependent Cellular Cytotoxicity
20%
Solid Tumor Therapy
20%
Selective Targeting
20%
In Vivo Antitumor Activity
20%
Dose Administration
20%
Endothelial Tumors
20%
Medicine and Dentistry
Tumor Cell
100%
Monoclonal Antibody
100%
Integrin
100%
Etaracizumab
100%
Malignant Neoplasm
37%
Solid Malignant Neoplasm
25%
Antineoplastic Activity
25%
Tumor Progression
25%
In Vitro
12%
Clinical Trial
12%
Metastatic Carcinoma
12%
Endothelial Cell
12%
Species Difference
12%
Angiogenesis
12%
Tumor Cell Line
12%
Flow Cytometry
12%
Drug Megadose
12%
Osteolysis
12%
Osteoclast
12%
Antiangiogenic
12%
Physical Disease by Body Function
12%
Biological Activity
12%
Phase II Trials
12%
Antibody Dependent Cellular Cytotoxicity
12%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Monoclonal Antibody
100%
Integrin
100%
Etaracizumab
100%
Malignant Neoplasm
37%
Tumor Growth
25%
Solid Malignant Neoplasm
25%
Antitumor Activity
25%
Clinical Trial
12%
Biological Activity
12%
Phase II Trials
12%
Flow Cytometry
12%
Metastasis
12%
Antiangiogenic
12%
Cytotoxicity
12%
Physical Disease by Body Function
12%
Immunology and Microbiology
Tumor Cell
100%
Monoclonal Antibody
100%
Integrin
100%
Etaracizumab
100%
Antineoplastic Activity
25%
Drug Megadose
12%
Species Difference
12%
Biological Activity
12%
Angiogenesis
12%
Blood Level
12%
Ovary
12%
Tumor Cell Line
12%
Osteolysis
12%
Osteoclast
12%
Prostate
12%
Antibody-Dependent Cell-Mediated Cytotoxicity
12%